SM Investments Recognized for Landmark Capital Market Deal
PASAY CITY, Philippines, Feb. 6, 2025 /PRNewswire/ -- SM Investments Corporation (SM Investments), the parent company of the SM Group, has been awarded the 'Philippine Capital Market Deal of the Year' by International Financing Review Asia (IFR Asia) for its successful issuance of a USD500 million five-year bond in 2024. This recognition underscores SM Investments' leadership in the capital markets and the strong confidence of global investors in the company's financial strength.
IFR Asia cited SM Investments' return to the US dollar bond market after a decade-long absence as a significant development for the Philippine corporate sector. The transaction, which was the largest five-year deal by a Philippine corporate in 2024, reopened the market amid volatile conditions and achieved competitive pricing at 35 basis points.
'This landmark transaction represents a major milestone for both SM Investments and the Philippine capital markets. The strong demand from investors reflects confidence in Philippine corporate issuers and underscores SM's reputation as a stable and well-managed investment option,' said Erwin G. Pato, Executive Vice President for Treasury, Finance, and Planning at SM Investments Corporation.
IFR Asia noted that SM Investments' bond issuance attracted significant investor interest, given the relative scarcity of corporate issuances from the Philippines in recent years. The transaction also marked SM Investments' first bond issuance since its USD350 million 10-year note in June 2014.
The deal was arranged by leading global financial institutions, with HSBC, JP Morgan, Standard Chartered, and UBS acting as joint lead managers and joint bookrunners. BDO Capital and Chinabank Capital also participated as joint lead managers.
International Financing Review Asia is a respected source of news and analysis on capital markets and investment banking, reinforcing the credibility of this recognition.
SM Investments' achievement highlights its commitment to financial excellence and its role in strengthening investor confidence in the Philippine market.
About SM Investments Corporation
SM Investments Corporation is one of the leading Philippine companies that is invested in market-leading businesses in retail, banking, and property. It also invests in ventures that capture high growth opportunities in the emerging Philippine economy.
SM's retail operations are the country's largest and most diversified, consisting of grocery stores, department stores and specialty retail stores. SM's property arm, SM Prime Holdings, Inc., is the largest integrated property developer in the Philippines with interests in malls, residences, offices, hotels, and convention centers as well as tourism-related property developments. SM's interests in banking are in BDO Unibank, Inc., the country's largest bank, and China Banking Corporation, the fourth largest private domestic bank.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Cyclic Materials Announces USD $25M Investment to Establish Centre of Excellence for Rare Earth Recycling in Kingston, Ontario
TORONTO--(BUSINESS WIRE)--Cyclic Materials, the advanced recycling company building a circular supply chain for rare earth elements (REEs), today announced a USD $25 million investment to launch North America's first Centre of Excellence for rare earth recycling in Kingston, Ontario, which will result in 45 new skilled jobs in the region. Spanning over 140,000 square feet, the first-of-its-kind facility will serve as Cyclic's industrial and innovation backbone, combining full-scale commercial processing and cutting-edge research and development (R&D) to address one of the world's most pressing supply chain challenges: the resilient sourcing of rare earth elements for use in permanent magnets. A Strategic Facility Serving a Circular Future The Kingston Centre of Excellence will house Cyclic Materials' first commercial 'Hub' processing unit, leveraging the company's proprietary REEPure SM technology. The facility is designed to convert 500 tonnes of magnet-rich feedstock annually into recycled Mixed Rare Earth Oxide (rMREO)—a product containing crucial components for permanent magnets used in EV motors, wind turbines, and consumer electronics such as Neodymium, Praseodymium, Terbium, and Dysprosium. Feedstock for this facility will be sourced from both Cyclic's Arizona-based 'Spoke', where end-of-life products will be processed, as well as a growing network of partners supplying magnet scrap from production. With operations set to begin in Q1 2026, rMREO from this facility will supply key partners within the magnet value chain, like Solvay, with whom Cyclic Materials signed an offtake agreement in 2024, providing a secondary resource of critical rare earth elements. The site will also house a state-of-the-art R&D center, including advanced labs and a mini-Spoke line, to accelerate process optimization and scale next-generation technologies across the rare earth value chain. Breaking Global Dependency with Local Innovation Today, less than 1% of rare earth elements are recycled, and global supply chains remain highly sensitive to growing geopolitical tensions and supply concentration. Cyclic Materials' proprietary MagCycle℠ and REEPure℠ technologies recover REEs from end-of-life products such as EVs, wind turbines, and data center hard drives—delivering a low-footprint, circular alternative to mining and a fast track to domestic supply security. 'With this Centre of Excellence, we're advancing our core mission: to secure the most critical elements of the energy transition through circular innovation,' said Ahmad Ghahreman, CEO of Cyclic Materials. 'Kingston is where Cyclic began—and now it's where we're anchoring our commercial future.' Kingston: The Cornerstone for the Next Generation of Cleantech Kingston has played a foundational role in the company's success—home to its commercial demonstration facilities and a deep bench of collaborators in research, engineering, and cleantech. The Centre of Excellence will build on robust partnerships with Queen's University, Kingston Process Metallurgy (KPM), RXN Hub, and Impact Chemistry, as well as support from national innovation programs including CMRDD (Critical Minerals Research, Development and Demonstration) from Natural Resources Canada, Sustainable Development Technology Canada (SDTC), and the National Research Council's Industrial Research Assistance Program (IRAP). The facility is expected to create over 45 highly qualified new jobs, with more than 20 hires already onboard. Recruitment has already started with key roles for plant operators, process technicians, and innovation staff. "We are thrilled to see Cyclic Materials' significant investment to establish their Centre of Excellence and Hub in Kingston, Ontario. This announcement not only creates high-quality jobs in the community but is a reflection of the expertise, talent, and supportive ecosystem Kingston has to offer companies,' said Shelley Hirstwood, Director of Business Development at Kingston Economic Development Corporation. 'We are proud to support Cyclic Materials' efforts to create a circular supply chain addressing Canada's critical minerals and rare earth elements." Scaling a North American Rare Earth Recycling Network This investment marks a pivotal step in Cyclic Materials' broader plan to scale its rare earth recycling infrastructure across North America and Europe. With strategic alliances including Solvay, Glencore, Lime, and Sims Lifecycle Solutions, the company is building a resilient, sustainable, and circular ecosystem for rare earth magnets—supporting the electrification of industries and the secure supply of critical materials. About Cyclic Materials Cyclic Materials, founded in 2021, is a cleantech company building a circular supply chain for rare earth elements (REEs) and other critical materials essential to the clean energy transition. Its innovative technology transforms end-of-life products into valuable raw materials used in EVs, wind turbines, and electronics. In 2023, the company launched a commercial demo facility using its MagCycle℠ process to recover rare earth magnets. In 2024, it opened a second facility in Kingston, Ontario, producing Mixed Rare Earth Oxide via its REEPure℠ hydrometallurgical process. With demand for REE-based magnets surging, Cyclic Materials is scaling globally across North America, Europe, and Asia. Mesa, Arizona, is its first U.S. location. In recognition of its pioneering work, it was named the #8 Most Innovative company in North America by Fast Company in 2025. Learn more at
Forbes
3 days ago
- Forbes
Billionaire Sy Family's SM Prime Earmarks $179 Million To Expand Hotel Footprint Amid Travel Boom
Conrad Manila, a five-star hotel overlooking Manila Bay, is one of the hospitality properties owned ... More by SM Prime. SM Prime Holdings—the real estate arm of the billionaire Sy family's SM Investments Corp—is spending about 10 billion pesos ($179 million) to expand its hotel footprint across the Philippines over the next five years amid a tourism boom. Under the five-year growth plan, SM Prime said it will build seven new hotels with a total of 1,321 hotel rooms. Once the projects, which will be funded by internally-generated cash, are completed by end-2029, the group will have 17 hotels with a total of 3,923 rooms, it added. Six of the new hotels will be branded the Park Inn by Radisson, while one will be developed under Radisson. The expansion—which is part of the 500-billion-peso investment announced by SM Prime in May—bolsters SM Hotels Convention Corp.'s position in the midscale and high-end segments while leveraging synergies with the SM Prime's diverse portfolio of shopping malls, office buildings, hotels and convention facilities. 'This rollout reflects our belief in the long-term potential of the Philippine domestic travel and tourism market,' Peggy Angeles, executive vice president of SM Hotels, said in a statement released on Tuesday. 'We are building on the strength of regional tourism while delivering quality accommodations that enhance the value of our ecosystem of malls, events spaces and mixed-use developments.' Just like in its shopping mall and residential projects, the new hotels will be developed outside of Metro Manila as SM Prime seeks to tap into the growing middle class in the provinces. Only one of the new SM hotels will be in Metro Manila, while the rest will be in various parts of the main island Luzon as well as Cebu City in central Philippines. 'Our hotels serve as catalysts for local economic activity,' Angeles said. 'We are focused on creating long-term value—through jobs, tourism flows and sustained growth that enhances SM Prime's diversified revenue base.' The SM group traces its roots to Henry Sy Sr., who sold overrun shoes in 1958 at a store in Manila he aptly called Shoemart. Following his death in 2019, his six children—Teresita, Elizabeth, Henry Jr, Hans, Herbert and Harley—inherited his fortune. With a net worth of $13 billion, the family is among the richest in the Philippines. Apart from its real estate portfolio, SM Investments has interests in banking, energy, retail, mining and shipping.
Business Insider
06-06-2025
- Business Insider
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.
